The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience

著者: William R. Hiatt, Sanjay Kaul, Robert J. Smith - New England Journal of Medicine, NEJM 2013 被引用: 204

A signal of cardiovascular harm with rosiglitazone led to a new FDA policy on diabetes-drug approval. As that signal has faded in recent analyses, should FDA policy change?